-
Mashup Score: 2IDHENTIFY trial: Impact of mutational burden and pattern on outcomes in patients with R/R IDH2-mutated AML - 10 hour(s) ago
Here, we summarize a post hoc analysis of the IDHENTIFY trial investigating the molecular characteristics and prognostic impact of co-occurring mutations in patients with R/R IDH2-mutated AML and treated with enasidenib.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3The Pre-MEASURE study: How does pretransplant IDH1 and IDH2 MRD affect posttransplant outcomes in patients with AML? - 2 day(s) ago
The AML Hub spoke to Gege Gui, National Institutes of Health, Maryland, US. We asked, How does pretransplant IDH1 and IDH2 MRD affect posttransplant outcomes in patients with AML?
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 14Low dose azacitidine + venetoclax as maintenance therapy for patients with AML in remission - 7 day(s) ago
Here, we summarize a phase II study investigating the safety and efficacy of low-dose azacitidine + venetoclax as maintenance therapy in patients with acute myeloid leukemia in remission after either intensive or low-intensity induction.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
On April 30, 2024, the U.S. FDA granted Orphan Drug Designation to IGNK001, an investigational allogeneic NK cell therapy derived from healthy donors, for the treatment of patients with AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Here, we summarize results from a pilot study by Wang et al. investigating the safety and tolerability of crenolanib plus intensive chemotherapy in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 33Gemtuzumab ozogamicin plus 7 + 3 induction therapy in patients with intermediate-risk ND AML - 13 day(s) ago
Here, we summarize a real-world retrospective analysis by Awada et al. investigating whether the addition of gemtuzumab ozogamicin to intensive 7 + 3 induction therapy is beneficial in patients with intermediate-risk ND AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
During the 6th European CAR T-Cell Meeting, the AML Hub spoke to Sarah Tettamanti, Tettamanti Foundation Research Center, Monza, IT. We asked, What are the challenges associated with CAR T-cell therapy in patients with AML?
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4U.S. FDA grants Breakthrough Therapy Designation for ziftomenib - 16 day(s) ago
On April 22, 2024, the U.S. FDA granted Breakthrough Therapy Designation to ziftomenib, a novel therapy that targets the menin-KMT2A/MLL protein-protein interaction, for the treatment of NPM1-mutated R/R AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet-
🚨 NEWS 🚨 @US_FDA grants Breakthrough Therapy Designation for ziftomenib, a novel therapy that targets the menin-KMT2A/MLL protein-protein interaction, for the treatment of NPM1-mutated AML. Read more here 👉 https://t.co/B7yl3hgANv #AMLsm #leusm #leukemia #MedicalEducation https://t.co/uIlePVyzDZ
-
-
Mashup Score: 5
Here, we summarize a validation of the Oncomine Myeloid Assay GX v2 in myeloid malignancies published by Zbieranski and Insuasti-Beltran.1 in The Journal of Molecular Diagnostics.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Annamycin granted Orphan Drug Designation by the EMA - 16 day(s) ago
On April 18, 2024, the European Medicines Agency granted Orphan Drug Designation to annamycin, a next-generation anthracycline, for the treatment of patients with AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
What are the molecular characteristics and prognostic impact of co-occurring mutations in patients with R/R IDH2-mutated AML who are treated with enasidenib? Find out more here: https://t.co/lb4lD0c28Z #AMLsm #leusm #leukemia #MedicalEducation https://t.co/TYbT5TaOh3